{"@context":{"@vocab":"https://schema.org/","dcterms":"http://purl.org/dc/terms/","prov":"http://www.w3.org/ns/prov#"},"@type":"ItemList","@id":"https://api.morvs.ai/api/v1/entity/PURR/timeline","_source":{"data_provider":"AI Analytics","brand_name":"MORVS","brand_url":"https://morvs.ai/","data_provider_url":"https://api.morvs.ai","license":"https://api.morvs.ai/license","usage_info":"https://api.morvs.ai/license","rights":"Source-specific terms apply; free or keyless access does not alter them.","generated_at":"2026-10-16T17:09:42.913Z","methodology_url":"https://api.morvs.ai/datasets/","primary_sources":{"sec.*":"https://www.sec.gov/edgar","fda.*":"https://api.fda.gov/","contracts":"https://api.usaspending.gov/","clinical.trials":"https://clinicaltrials.gov/","lobbying.filings":"https://lda.senate.gov/","epa.facilities":"https://echo.epa.gov/","court.dockets":"https://www.courtlistener.com/","cfpb.complaints":"https://www.consumerfinance.gov/data-research/consumer-complaints/","nih.grants":"https://api.reporter.nih.gov/","fed.enforcement":"https://www.federalreserve.gov/supervisionreg/enforcementactions.htm","nhtsa.recalls":"https://api.nhtsa.gov/recalls/"}},"entity":{"entity_id":10019,"canonical_name":"Hyperliquid Strategies Inc","cik":"0002078856","uei":null,"lei":null,"duns":null,"ticker":"PURR"},"window_days":180,"min_importance":0,"sources_queried":["sec.filings","sec.insider","sec.form144","sec.13dg","fda.recalls","fda.labels","contracts","clinical.trials","lobbying.filings","epa.facilities","uspto.patents","court.dockets","cfpb.complaints","nih.grants","fed.enforcement","nhtsa.recalls","doj.press","dol.form5500"],"importance_reference":{"fda.recall Class I":100,"clinical trial terminated":80,"securities class action":80,"antitrust suit":75,"schedule 13D":75,"patent litigation":70,"form144 large ($50M+)":75,"10-K restatement":75,"phase3 trial completed":70,"EPA significant violator":70,"phase3 trial in progress":60,"insider purchase":50,"phase2 trial":45,"8-K":35,"lobbying filing":30,"fda.label":30,"phase1 trial":30,"fda.recall Class III":25},"vertical_counts":{"sec":28},"count":28,"timeline":[{"ts":"2026-10-02","kind":"sec.filing","form_type":"DEF 14A","title":"DEF 14A — Hyperliquid Strategies Inc — 2026-10-02","url_slug":"/sec/cik-0002078856/def-14a/0001193125-26-412569","accession_number":"0001193125-26-412569","importance":40},{"ts":"2026-10-02","kind":"sec.filing","form_type":"ARS","title":"ARS — Hyperliquid Strategies Inc — 2026-10-02","url_slug":"/sec/cik-0002078856/ars/0001193125-26-412579","accession_number":"0001193125-26-412579","importance":30},{"ts":"2026-10-01","kind":"sec.insider.2037","reporter":"Bhatt Nailesh","title":null,"shares":2037,"price_per_share":null,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-10-01","kind":"sec.insider.3056","reporter":"KING THOMAS C.","title":null,"shares":3056,"price_per_share":null,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-10-01","kind":"sec.insider.3056","reporter":"Rosengren Eric S","title":null,"shares":3056,"price_per_share":null,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-10-01","kind":"sec.insider.1358","reporter":"LEIBOWITZ LAWRENCE E","title":null,"shares":1358,"price_per_share":null,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-09-30","kind":"sec.filing","form_type":"4","title":"4 — Hyperliquid Strategies Inc — 2026-09-30","url_slug":"/sec/cik-0002078856/4/0001193125-26-409273","accession_number":"0001193125-26-409273","importance":30},{"ts":"2026-09-23","kind":"sec.filing","form_type":"424B3","title":"424B3 — Hyperliquid Strategies Inc — 2026-09-23","url_slug":"/sec/cik-0002078856/424b3/0001193125-26-399511","accession_number":"0001193125-26-399511","importance":30},{"ts":"2026-09-23","kind":"sec.filing","form_type":"EFFECT","title":"EFFECT — Hyperliquid Strategies Inc — 2026-09-23","url_slug":"/sec/cik-0002078856/effect/9999999995-26-003046","accession_number":"9999999995-26-003046","importance":30},{"ts":"2026-09-15","kind":"sec.filing","form_type":"S-1","title":"S-1 — Hyperliquid Strategies Inc — 2026-09-15","url_slug":"/sec/cik-0002078856/s-1/0001193125-26-391097","accession_number":"0001193125-26-391097","importance":65},{"ts":"2026-09-15","kind":"sec.filing","form_type":"8-K","title":"8-K — Hyperliquid Strategies Inc — 2026-09-15","url_slug":"/sec/cik-0002078856/8-k/0001193125-26-391090","accession_number":"0001193125-26-391090","importance":35},{"ts":"2026-09-15","kind":"sec.filing","form_type":"PRE 14A","title":"PRE 14A — Hyperliquid Strategies Inc — 2026-09-15","url_slug":"/sec/cik-0002078856/pre-14a/0001193125-26-392149","accession_number":"0001193125-26-392149","importance":30},{"ts":"2026-09-14","kind":"sec.filing","form_type":"8-K","title":"8-K — Hyperliquid Strategies Inc — 2026-09-14","url_slug":"/sec/cik-0002078856/8-k/0001193125-26-389910","accession_number":"0001193125-26-389910","importance":35},{"ts":"2026-09-01","kind":"sec.filing","form_type":"8-K","title":"8-K — Hyperliquid Strategies Inc — 2026-09-01","url_slug":"/sec/cik-0002078856/8-k/0001193125-26-378589","accession_number":"0001193125-26-378589","importance":35},{"ts":"2026-08-27","kind":"sec.filing","form_type":"10-K","title":"10-K — Hyperliquid Strategies Inc — 2026-08-27","url_slug":"/sec/cik-0002078856/10-k/0001193125-26-370281","accession_number":"0001193125-26-370281","importance":55},{"ts":"2026-08-27","kind":"sec.filing","form_type":"8-K","title":"8-K — Hyperliquid Strategies Inc — 2026-08-27","url_slug":"/sec/cik-0002078856/8-k/0001193125-26-369668","accession_number":"0001193125-26-369668","importance":35},{"ts":"2026-08-27","kind":"sec.filing","form_type":"424B3","title":"424B3 — Hyperliquid Strategies Inc — 2026-08-27","url_slug":"/sec/cik-0002078856/424b3/0001193125-26-370731","accession_number":"0001193125-26-370731","importance":30},{"ts":"2026-08-27","kind":"sec.filing","form_type":"424B3","title":"424B3 — Hyperliquid Strategies Inc — 2026-08-27","url_slug":"/sec/cik-0002078856/424b3/0001193125-26-370737","accession_number":"0001193125-26-370737","importance":30},{"ts":"2026-08-06","kind":"sec.filing","form_type":"SCHEDULE 13G/A","title":"SCHEDULE 13G/A — Hyperliquid Strategies Inc — 2026-08-06","url_slug":"/sec/cik-0002078856/schedule-13g-a/0001193125-26-337954","accession_number":"0001193125-26-337954","importance":30},{"ts":"2026-08-04","kind":"sec.filing","form_type":"EFFECT","title":"EFFECT — Hyperliquid Strategies Inc — 2026-08-04","url_slug":"/sec/cik-0002078856/effect/9999999995-26-002533","accession_number":"9999999995-26-002533","importance":30},{"ts":"2026-07-21","kind":"sec.filing","form_type":"S-1/A","title":"S-1/A — Hyperliquid Strategies Inc — 2026-07-21","url_slug":"/sec/cik-0002078856/s-1-a/0001193125-26-309340","accession_number":"0001193125-26-309340","importance":30},{"ts":"2026-07-01","kind":"sec.insider.a","reporter":"LEIBOWITZ LAWRENCE E","title":null,"shares":2117,"price_per_share":null,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-07-01","kind":"sec.insider.a","reporter":"KING THOMAS C.","title":null,"shares":4764,"price_per_share":null,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-07-01","kind":"sec.insider.a","reporter":"Bhatt Nailesh","title":null,"shares":1588,"price_per_share":null,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-07-01","kind":"sec.insider.a","reporter":"Rosengren Eric S","title":null,"shares":4764,"price_per_share":null,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-06-26","kind":"sec.filing","form_type":"8-K","title":"8-K — Hyperliquid Strategies Inc — 2026-06-26","url_slug":"/sec/cik-0002078856/8-k/0001193125-26-285672","accession_number":"0001193125-26-285672","importance":35},{"ts":"2026-06-25","kind":"sec.filing","form_type":"S-1/A","title":"S-1/A — Hyperliquid Strategies Inc — 2026-06-25","url_slug":"/sec/cik-0002078856/s-1-a/0001193125-26-283059","accession_number":"0001193125-26-283059","importance":30},{"ts":"2026-06-23","kind":"sec.insider.a","reporter":"Nieuwkoop Jeroen","title":"Chief Operating Officer","shares":421623,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15}]}